Sells three FDA-approved neurological drugs that rely on government-granted exclusivity periods to block generic competition.
At a glance
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- ScaleMarket cap is above the global median
Sells three FDA-approved neurological drugs that rely on government-granted exclusivity periods to block generic competition.
Catalyst Pharmaceuticals sells three FDA-approved drugs for rare neurological conditions, where the protection keeping competitors out is not a patent but an orphan drug exclusivity period — a regulatory clock the FDA starts at approval and that cannot be reset no matter how much additional clinical work the company does. That clock is what makes the business viable: while it runs, no generic manufacturer can enter the market for amifampridine phosphate, which allows Catalyst to set a list price high enough to support specialty pharmacy distribution and insurance reimbursement negotiations for a patient population too small to sustain volume-driven revenue. Neurologists who prescribe these drugs have learned specific dosing protocols and their patients are enrolled in support programs that handle insurance paperwork, so switching to an alternative requires retraining and restarting that paperwork process — which slows substitution even when a competitor eventually arrives. When the exclusivity period on FIRDAPSE expires, however, that regulatory barrier simply disappears: amifampridine phosphate has no proprietary chemistry underneath it, generic manufacturers can enter immediately, and there is no clinical or regulatory tool available to rebuild the wall.
How does this company make money?
The company earns money each time a prescription of FIRDAPSE, AGAMREE, or FYCOMPA is filled through a specialty pharmacy. The drug is billed at a manufacturer list price, and then the company pays negotiated rebates back to insurance companies and pharmacy benefit managers. What remains after those rebates is the revenue the company keeps per prescription fill.
What makes this company hard to replace?
Neurologists who prescribe amifampridine phosphate have learned its specific dosing protocols, and switching to a different Lambert-Eaton treatment would require retraining. Patients are also enrolled in support programs tied to specialty pharmacies that manage the prior authorization paperwork their insurance requires — moving to a different drug means restarting that process. Finally, the FDA-mandated Risk Evaluation and Mitigation Strategies attached to these specific formulations create an additional procedural hurdle that neurologists must clear before they can prescribe any alternative.
What limits this company?
The diseases these drugs treat are rare by definition, so the number of patients is small and fixed. The compounds used in FIRDAPSE and AGAMREE cannot share production lines — each requires its own manufacturing process and quality checks built around that specific drug. That means the company cannot spread costs across a larger volume to make up for lost revenue when the exclusivity period ends.
What does this company depend on?
The company cannot operate without FDA marketing approvals for FIRDAPSE, AGAMREE, and FYCOMPA. It also relies on specialty pharmacy distribution networks that handle the complicated logistics of rare disease medications, manufacturing partners that produce amifampridine phosphate, vamorolone, and perampanel, insurance coverage decisions from Medicare and commercial payers that make those drugs affordable to patients, and the Orphan Drug Act exclusivity periods that keep generic competitors out of the market.
Who depends on this company?
Neurologists treating Lambert-Eaton Myasthenic Syndrome patients depend on this company for access to amifampridine phosphate — if it disappeared, those patients would have no equivalent approved option. Duchenne muscular dystrophy treatment centers rely on vamorolone through AGAMREE and would have to find alternative corticosteroid therapies if it became unavailable. Epilepsy patients taking FYCOMPA would need to switch to a different seizure medication if perampanel supply was cut off.
How does this company scale?
Adding a new FDA-approved rare disease drug allows the company to reuse its patient support programs and specialty pharmacy relationships without rebuilding them from scratch. What does not get easier as the company grows is manufacturing — each neurological compound requires its own production process and quality controls, so producing more of one drug does not reduce the cost or complexity of producing another.
What external forces can significantly affect this company?
Medicare drug price negotiation rules under the Inflation Reduction Act could force lower reimbursement rates even for orphan drugs, cutting into the revenue the company earns per prescription. Regulatory decisions by the European Medicines Agency affect whether development partnerships and licensing deals outside the United States are possible. At the state level, Medicaid formulary restrictions can limit which patients are allowed access to high-cost rare disease treatments, shrinking the effective patient pool.
Where is this company structurally vulnerable?
When FIRDAPSE's orphan drug exclusivity period expires, the FDA restriction on competitor trials simply ends. At that moment, generic manufacturers can produce amifampridine phosphate freely, because the compound itself has no patent protection. There is no additional clinical work the company can do to restart that clock, and no other regulatory barrier standing between its largest product and immediate generic competition.
Sign in to view price data.
Sign inStructural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph